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Abstract  
Poorly differentiated thyroid carcinoma (PDTC) is a follicular cell-derived tumor which was 
recognized as a distinct entity by the WHO in 2004. The natural history and pathological 
features of PDTC are reported to be intermediate between those of well-differentiated and 
undifferentiated (anaplastic) thyroid carcinomas.  
Preoperative identification of PDTC could facilitate better initial patient management in many 
cases, namely more extensive surgery, without any delay. However, according to some experts, 
a diagnosis of PDTC can only be rendered on histologic specimens based on criteria 
recommended in the “Turin proposal”. Actually PDTC recognition on routine thyroid cytology 
presents a notable challenge. Although high-grade features (namely necrosis and mitoses) can 
be recognized in fine-needle aspiration material, other cytomorphological features have limited 
value for the preoperative diagnosis of PDTC and cytomorphologic features for a definitive 
diagnosis of PDTC have not yet been clearly defined. Here, we review the current status and 
future prospects for cytologic recognition of PDTC; we emphasize the features that should raise 
suspicion of this rare condition in fine-needle aspiration cytology and provide an update on 
molecular features and management of PDTC.  
 
 
Keywords: thyroid; poorly differentiated thyroid carcinoma; fine-needle aspiration; cytological 
features; review.  
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Introduction 
Poorly differentiated thyroid carcinoma (PDTC) is a neoplasm with morphological features and 
biological behavior intermediate between well-differentiated thyroid carcinoma (WDTC) and 
undifferentiated (anaplastic) thyroid carcinoma (ATC).1 According to current models, PDTC may 
either develop by dedifferentiation of WDTC, or de novo from benign thyroid follicular cells; it 
can also represent an intermediate step in the progression to ATC.2-4 Currently, the histologic 
diagnosis of PDTC is based on the “Turin criteria”, which include the presence of solid, 
trabecular, or insular (STI) patterns and at least one of convoluted nuclei, mitoses (≥ 3 per 10 
HPF), or necrosis, in the absence of nuclear features of papillary thyroid carcinoma (PTC).5 
The lack of consensus on the definition of PDTC before the definition of the “Turin 
criteria” in 2006 resulted in variable data regarding its epidemiology, as the term PDTC 
encompassed a heterogeneous group of tumors.6 More recent studies reported its prevalence 
as less than 1% of all thyroid malignancies in Japan, 1.8% in the United States, and up to 6.7% in 
northern Italy.7, 8 The mean age at presentation is between 55 and 63 years, with the youngest 
patient being 9 years old. A slight female preponderance has been described.4, 6, 8-10 
The management of patients with PDTC overlaps with that of patients with WDTC, but 
the clinical response is less favorable due to the more aggressive nature of the disease; thus the 
overall 10-year survival rate is approximately only 50%.11, 12 The presence of even a minor 
component of PDTC in an otherwise WDTC can potentially impact patient prognosis.13 
Molecular studies have demonstrated that PDTCs frequently carry RAS or BRAF mutations, also 
found in WDTC, as well  as additional alterations such as TERT promoter and TP53 mutations; 
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the latter two are thought to be involved in the progression of WDTCs towards the less 
differentiated PDTC and ATC.14 
The recognition of PDTC as a distinct entity and the introduction of better defined 
histomorphologic criteria facilitated a uniform diagnostic approach for pathologists; however, 
the cytological diagnosis of PDTC remains problematic.5 In various studies, approximately one 
fourth of all PDTC aspirations were reported as malignant but classified as WDTC, and one third 
were reported as follicular neoplasm/suspicious for a follicular neoplasm (FN/SFN); such may 
lead to a less extensive initial procedure (notably lobectomy instead of total thyroidectomy), 
necessitating additional surgery (i.e., completion thyroidectomy with or without lymph node 
dissection).15-18 
The aim of this review is to assess the current literature to investigate the present and 
future roles of cytology and molecular analysis in the diagnosis of this uncommon but 
aggressive thyroid carcinoma.  
 
Historical perspective 
In 1983, Sakamoto et al. proposed the term “poorly differentiated thyroid carcinoma” to 
designate a variant of papillary and follicular thyroid carcinomas that was less differentiated 
and had an aggressive behavior although it was lacking features of ATC. The histologic diagnosis 
relied on the presence of a solid, trabecular, or scirrhous growth pattern.9 Shortly thereafter, 
Carcangiu et al. reported on the same entity, restricting the use of the term “PDTC” to “insular” 
patterned tumors in the presence of high-grade features, such as necrosis with the formation of 
“peritheliomatous” structures, capsular and vascular invasion, and mitotic activity.4 Although 
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the 2004 WHO Classification of Tumors of Endocrine Organs classified PDTC as a distinct tumor 
type,1 its diagnostic criteria were not well defined, and their evaluation in routine clinical 
practice was prone to subjectivity.  
In 2006, a consensus conference for PDTC was held in Turin, Italy.5 Pathologists from 
Italy, Japan, and the United States reviewed a cohort of 83 cases which had been selected 
according to the presence of solid, trabecular, insular (STI) growth patterns. The result was the 
proposition of a set of histologic criteria for the diagnosis of PTDC, which are in current use. 
Thus, a diagnosis of PDTC requires (i) the presence of an STI growth pattern; (ii) the absence of 
PTC nuclear features; and (iii) at least one of the following features: convoluted nuclei, ≥3 
mitoses per 10 HPF, and/or necrosis.5 
  An alternative classification system to the Turin criteria has been proposed by Hiltzik et 
al. in 2006 and is based on the experience at the Memorial Sloan Kettering Cancer Center 
(MSKCC); they reported that PDTC defined on the basis of necrosis and mitoses (≥5 per 10 HPF) 
constitutes a group of tumors that is more homogeneous than the group of PDTC defined by 
growth pattern and is more aggressive.19 They also found that these patients with PDTC defined 
by their criteria have an outcome intermediate between that of well-differentiated PTC and 
FTC, and that of highly aggressive ATC, with an overall survival (OS) at 5 years of 60% compared 
with 98%, and 0%, for WDTC and ATC, respectively. The authors also compared the outcome of 
PDTC defined on the basis of necrosis and/or mitoses to that of PDTC classified according to the 
Turin criteria: the latter also showed an intermediate prognosis between WDTC and ATC, but 
when the two OS curves were compared, the OS rate of PDTC according to MSKCC criteria (60% 
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at 5 years) appeared to be worse than the OS rate of PDTC according to Turin criteria (83% at 5 
years).5, 19 
 In the new WHO Classification of Tumors of Endocrine Organs, published in 2017, PDTC 
is still be considered as a distinct neoplastic entity.20  
 
Cytological features of PDTC 
According to established practices, a definitive diagnosis of PDTC is primarily limited to 
histopathology specimens. Despite attempts by some groups, there are no universally accepted 
cytological criteria for the diagnosis of PDTC that can be applied to thyroid fine-needle 
aspiration (FNA) material. This is unfortunate because the preoperative identification of PDTC 
could lead in many cases to a more aggressive initial management of these patients:15-18 in fact, 
in the frame of The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC), PDTC is 
often classified as a follicular lesion (diagnostic category IV, FN/SFN), which entails a surgical 
lobectomy.21  
 In 2009, Bongiovanni et al. studied a series of 40 histologically-proven PDTCs and 
compared their cytological features with a control group of 40 WDTCs. The combined presence 
on FNA of STI cytoarchitectural pattern, single cells, high nuclear/cytoplasmic (N/C) ratio, and 
severe crowding was highly predictive of PDTC.15 In 2012, Barwad et al., conducted a study on 
insular-patterned PDTC lesions, and the most frequent findings were hypercellularity, 
monomorphic small cells arranged in solid clusters or single cells, scant to moderate cytoplasm, 
and the presence of mitotic activity.16 Similarly, in 2015 Kane et al. analyzed a series of 44 PDTC 
cases and compared a subset of selected cytologic features with WDTC. According to their 
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findings, hypercellularity, insular pattern, small cell size, high N/C ratio, granular chromatin, 
severe nuclear overlapping, mild nuclear pleomorphism, abrupt nucleomegaly, apoptosis, 
necrosis, and mitosis were observed more commonly in PDTC. All of these features showed 
statistical significance in univariate analysis, whereas only small cell size remained significant 
using logistic regression analysis.17 In 2016, Purkait et al. reported that the presence of cell 
nests and three-dimensional clusters, endothelial wrapping of cell groups, singly dispersed cells, 
and peripheral alignment of nuclei within nests were the most important cytological features 
for identifying PDTC in their series of 7 FNA cases.18 Interestingly, this was the only series that 
also reported the presence of nuclear features of PTC. The latter may be the reason why some 
cases were classified as atypia of undetermined significance/follicular lesion of undetermined 
significance (AUS/FLUS) and suspicious for malignancy (SM).  
When these cytologic studies are considered together, insular or solid patterns and high 
cellularity emerge as the most common cytologic features as emphasized by all four studies.15-18 
Single cell pattern, high N/C ratio, granular chromatin and mitotic activity were described in 
different combinations by three of the four series. Endothelial wrapping of cell clusters, scant 
cytoplasm, nuclear pleomorphism, nuclear crowding/overlapping and apoptosis were less 
frequently reported (Table 1) (Figure 1).15-18 A few recent case reports have contributed to the 
literature on the topic. One of them described cytological findings highly suggestive of PDTC, 
such as hypercellular smears composed of monomorphic small follicular cells with scant 
cytoplasm, arranged in cohesive clusters or singly dispersed;22 others, instead, did not identify 
any features as characteristic of PDTC.23-25 
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  Of the total 101 cases in the literature, only 27 (27%) were preoperatively recognized as 
PDTC.15-18 The remaining 74 cases comprised the following diagnoses: poorly differentiated 
carcinoma, not otherwise specified (NOS) (n=7, 7%); carcinoma, NOS (n=4, 4%); papillary 
thyroid carcinoma (PTC) (n=10, 10%); medullary thyroid carcinoma (MTC) (n=3, 3%); follicular 
variant (FV)-PTC (n=13, 13%); suspicious for PTC (n=1, 1%); follicular neoplasm or suspicious for 
follicular neoplasm (FN/SFN) (n=34, 33%); and lastly, atypia of undetermined 
significance/follicular lesion of undetermined significance (AUS/FLUS) (n=2, 2%) (Figure 2).26  
 One third of the reported PDTC cases were initially diagnosed as FN/SFN, which is not 
surprising considering that PDTC lacks, by definition, the characteristic nuclear features of PTC 
and can have overlapping features with follicular adenoma/carcinoma with respect to 
hypercellularity, cellular monotony, and cytoarchitecture.5, 18 However, because a report of 
FN/SFN commonly leads to hemithyroidectomy or molecular testing as opposed to direct total 
thyroidectomy with possible neck lymph node dissection, this misclassification can have 
important implications for clinical management (Figure 3).11   
 The specific diagnosis of PDTC or PDC, NOS was made in only 34% of cases. Overall, the 
lack of accepted criteria for diagnosing PDTC on FNA material reflects the difficulty in accurately 
transferring the histologic diagnostic criteria of PDTC onto cytologic criteria.  The reason is that 
the histologic criteria of PDTC overlap in cytology with features of WDTC. Convoluted 
“raisinoid” nuclei can be found in a variety of conditions, mainly PTC, and are not specific for 
PDTC. In addition, the frequent coexistence of a WDTC component can easily confound the 
diagnosis of PDTC on FNA.26  Moreover, an oncocytic variant of PDTC has been described at the 
histological level, raising the additional challenge of distinguishing between PDTC and FN/SFN, 
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oncocytic type (Figure 4).27, 28 At best, the diagnosis of PDTC can be suggested in a subset of 
FNA cases, but consistent accurate diagnosis based upon cytomorphology has yet to be 
achieved. 
Indeed, while different series have shown a variable distribution of cases according to 
TBSRTC, the overall percentage of PDTC cases, which are accurately recognized on FNA 
samples, has not improved over time (Figure 5). 
 
Differential diagnosis and immunohistochemistry  
The differential diagnosis of PDTC includes WDTC (PTC and FC), ATC, as well as MTC and 
secondary thyroid neoplasms.  In particular, a subset of PDTC can exhibit a predominantly 
single-cell pattern suggestive of MTC.  Kane et al. described 3 such PDTC cases.17  For the 
differential diagnosis of PDTC with MTC or secondary neoplasms, immunostaining on cytology 
slides or on cell block material can effectively discriminate between these possibilities: PDTC is 
immunoreactive for thyroglobulin and, unlike MTC, it is negative for calcitonin and 
carcinoembryonic antigen (CEA).26, 29 However, immunohistochemistry is useless in differential 
diagnosis with other thyroid cancers of follicular derivation: PAX-8 and TTF-1 are used to prove 
thyroid origin in differential diagnosis with secondary thyroid neoplasms, but they are not 
speficic for PDTC.  
 
Molecular features 
Less differentiated thyroid carcinomas have been shown to harbor a higher mutation burden.14, 
30-32 In cases of PDTC, the median number of mutations was found to be two.30 Recent 
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molecular studies using next-generation sequencing (NGS) on aggressive thyroid carcinomas 
analyzed a total number of 87 PDTCs, showing that mutually exclusive BRAFV600E and RAS 
mutations represent the main drivers in PDTC, being present in 33% and 45% of cases, 
respectively.14, 30, 31 Landa et al. observed an interesting relationship between PDTC BRAF/RAS 
mutation status and histological features: among PDTC diagnosed according to the Turin 
criteria, 92% harbored RAS mutations, whereas among PDTC diagnosed as proposed by Hiltzik 
et al. (necrosis and/or ≥ 5 mitoses per 10 HPF), BRAFV600E mutations were found in 81%.30 
Similar to WDTC, the presence of BRAFV600E or RAS mutations correlated with the metastatic 
pattern, with BRAF-mutant PDTC preferentially metastasizing to regional lymph nodes and RAS-
mutant PDTC having a higher rate of systemic metastases.30 
 In addition to mutations shared with PTC and FTC, other genetic alterations exist in 
PDTC that are frequently detected in less differentiated tumors. Notably, mutations in the 
promoter of telomerase reverse transcriptase (TERT) have been found in approximately 40% of 
PDTC, a prevalence intermediate between the more differentiated PTC (10%) and the 
undifferentiated ATC (73%). Mutations in TERT have been reported to correlate with aggressive 
clinical behavior, regional and distant metastases and disease-specific mortality.14, 32 TERT 
mutations occur as a subclonal event in PTC, while they seem to be clonal in PDTC and ATC; 
therefore, they are considered a potential step in the development of aggressive thyroid 
cancer.14, 30 
TP53 mutations, which are extremely rare in PTC and FTC, are reported in 10-26% of 
PDTC; they seem to play an important role in the dedifferentiation of WDTCs, and they are 
regarded as late events in tumor evolution.30, 33 Accordingly, in tumors presenting both papillary 
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and undifferentiated components, TP53 mutations have been found only in the 
undifferentiated component.34 Mutations in the eukaryotic translation initiation factor EIF1AX 
are present in 11% of PDTC: these mutations are reported in only 1% of PTC, where they occur 
in a mutually exclusive manner with BRAFV600E and RAS mutations;30 in addition, using NGS, 
Landa et al. identified a number of novel genes that can be mutated in PDTC, at frequencies of 
1-4%.30 When microRNA (miRNA) expression profiles were investigated, miR-150, miR-183-3p, 
miR-221 and miR-222 were the most dysregulated miRNAs, with a promising role for distinction 
between WDTC and PDTCs.35 
 The available data on molecular features of PDTC are based on analyses of 
histologically-confirmed tumors. For the time being, the utility of molecular testing to identify 
PDTC cases in cytologic specimens has not been well documented. Given that a high percentage 
of PDTC are classified cytologically within the indeterminate FN/SFN Bethesda category (Figure 
2), molecular testing could be useful, in a subset of cases, for their diagnosis. Or at the least, 
results of molecular testing could help triage cases for more aggressive initial management. 
Indeed, the 2015 American Thyroid Association guidelines stipulate that molecular screening 
may be used for indeterminate thyroid aspirations, though they do not make specific reference 
to the molecular diagnosis of PDTC (recommendation 15).36 In-house or commercially available 
mutation panel tests could be useful to identify mutations (notably TERT, TP53 and EIF1AX), 
which are more common in advanced, aggressive and/or dedifferentiated carcinomas, including 
PDTC.14, 30    
 
 
12 
 
Prognosis and management 
PDTC is associated with an intermediate prognosis between WDTC and ATC. A high rate of local 
recurrence, frequent distant metastases, and extrathyroidal invasion characterize the clinical 
course of PDTC; regional lymph node metastases are present at the time of diagnosis in more 
than 50% of patients. The latter are subject to detection by FNA. The European Society of 
Medical Oncology (ESMO) clinical guidelines recommend central compartment and/or lateral 
neck lymph node dissection be considered in addition to total thyroidectomy in the initial 
surgical management of PDTC. Suppression of TSH with levothyroxine should be started 
immediately after surgery.11 Being less differentiated compared to WDTC, PDTC cells are even 
less able to take up and organify iodine and to secrete thyroglobulin under the stimulus of 
thyroid-stimulating hormone (TSH). Nevertheless, the initial management is similar to that of 
WDTC, and it normally includes radioactive iodine (131I) therapy after surgery, especially since in 
many cases there is an admixture of PDTC and WDTC components in the same tumor.37 
However, the treating clinician must be aware of two important caveats: (i) The tumor may be 
or may become radioiodine-refractory; thus, it is prudent to perform imaging by 18FDG-PET, 
whether or not there is radioiodine uptake of the post-treatment scan. (ii) The level of 
thyroglobulin (if it is even detectable) may underestimate the volume of disease present, 
complicating the follow-up; thus, periodic imaging by 18FDG-PET or another cross-sectional 
modality should be considered during follow-up. Overall, the management of PDTC should 
follow the principles of radioiodine-refractory WDTC. External beam radiation therapy (EBRT) 
may be used for unresectable disease or persistent locoregional disease after surgery; 
chemotherapy achieves only transient and incomplete responses.11, 37 Recently, systemic 
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therapies using tyrosine kinase inhibitors (sorafenib and lenvatinib) have been approved for 
radioiodine-refractory WDTC;38, 39 these drugs should then be considered for use in progressive 
cases of PDTC that are radioiodine-refractory.  
 
Conclusions 
Despite increased awareness of PDTC after its recognition as a distinct entity by the WHO in 
2004 and the development of defined histological criteria in 2006 (“Turin Criteria”) and in 2006 
(“MSKCC definition”), the cytologic diagnosis of PDTC has remained a challenge for 
cytopathologists. Insular or solid architecture, hypercellularity, high N/C ratio, and mitotic 
activity are features that may suggest a diagnosis of PDTC in a thyroid FNA. Still, accurate FNA 
diagnosis of PDTC remains an elusive goal.  The cytologic accuracy for PDTC may be improved 
via molecular testing for cases in the indeterminate categories of TBSRTC to identify PDTC-
related genetic alterations frequently associated with an aggressive biologic behavior. 
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Figure legends 
Figure 1. Cytomorphological features of poorly differentiated thyroid carcinoma. (A) Smears are 
usually hypercellular, often with a background of cellular or necrotic debris and devoid of 
colloid. A minor follicular architecture is frequently present (smear, May-Grunwald Giemsa 
[MGG] stain, x100). (B) In clear-cut cases an insular arrangement of follicular cells can be seen 
(smear, Papanicolaou stain, x400). (C) A predominant single-cell pattern with high 
nuclear/cytoplasmic ratio can also be observed and may be the only architectural pattern 
present (smear, Papanicolaou stain, x400). (D) In the same case, by MGG staining, a mitotic 
figure was also present (arrow). The differential diagnosis with medullary thyroid carcinoma 
and anaplastic carcinoma can be addressed with the help of immunocytochemistry and clinico-
pathological correlation (smear, MGG stain, x400).  (E) A cluster of follicular cells with 
microfollicular and vague insular architecture. Note the granular chromatin and conspicuous 
nucleoli. Not surprisingly this case was diagnosed as follicular neoplasm/suspicious for a 
follicular neoplasm (smear, Papanicolaou stain, x400). (F) Another example of a loosely 
cohesive cluster of follicular cells with delicate cytoplasm and diagnosed as follicular 
neoplasm/suspicious for a follicular neoplasm (smear, Papanicolaou stain, x400).  
Figure 2. Preoperative fine-needle aspiration diagnosis of poorly differentiated thyroid 
carcinoma as reported in literature series and subdivided according to The Bethesda System for 
Reporting Thyroid Cytopathology.  
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Figure 3. A 72 year old man was diagnosed with a FN/SFN on cytology. (A) The smear shows 
hypercellularity and some microfollicular structures (arrows) next to oval (“insular”) aggregates 
of thyrocytes (smear, Papanicolaou stain, x400). (B) At higher power, many round to oval 
aggregates were observed and could have raised the suspicion of a PDTC component as well 
(smear, MGG stain, x40). 
Figure 4. Main cytomorphological features of oncocytic (Hürthle cell) poorly differentiated 
thyroid carcinoma in a 68 year old female. Clinically, the nodule appeared over several months 
and was limited to the thyroid gland. (A) The smear shows isolated-cell architecture with 
follicular cells having abundant, granular and eosinophilic cytoplasm and low to intermediate 
N/C ratio. Some nuclei were apoptotic and the background contained necrosis (smear, 
Papanicolaou stain, x100). (B) The same features were present in the cell block, with isolated 
oncocytic cells and necrotic debris. The cytological diagnosis was suspicious for malignancy (cell 
block, Haematoxylin and eosin stain, x100).  (C) Grossly, the mass was 6.5 x 5 x 5 cm in 
dimension, well circumscribed, limited to the thyroid gland, and showed a mahogany brown 
appearance. (D) On histology, insular structures with punctate foci of necrosis were easily 
identified. Cells had a oncocytic cytoplasm and a dyshesive pattern. Extensive capsular and 
vascular invasion were identified (Haematoxylin and eosin stain, x100).  
Figure 5. Preoperative fine-needle aspiration diagnoses of reported series of poorly 
differentiated thyroid carcinoma grouped into diagnostic categories according to the Bethesda 
System for Reporting Thyroid Cytopathology. 
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Table 1. Cytological features associated with poorly differentiated thyroid carcinoma.  
 Frequency p value  Reference  
General features 
Pattern    
Insular, solid, trabecular 92.5% (37/40) <0.001 Bongiovanni et al. (15) 
Insular 79.5% (35/44) <0.001 Kane et al. (17) 
Solid 100% (7/7) N/A Purkait et al. (18) 
 100% (10/10) N/A Barwad et al. (16) 
Single cells 75% (30/40) <0.0001 Bongiovanni et al. (15) 
 100% (10/10) N/A Barwad et al. (16) 
Singly dispersed, loosely cohesive cells 100% (7/7) N/A Purkait et al. (18) 
Three-dimensional groups 100% (7/7) N/A Purkait et al. (18) 
High cellularity 60% (24/40) 0.007 Bongiovanni et al. (15) 
 71.4% (5/7) N/A Purkait et al. (18) 
 100% (10/10) N/A Barwad et al. (16) 
 84.1% (37/44) 0.001 Kane et al. (17) 
Necrosis 15% (6/40) 0.025 Bongiovanni et al. (15) 
 34.1% (15/44) 0.001 Kane et al. (17) 
Background debris 15% (6/40) <0.025 Bongiovanni et al. (15) 
Transgressing endothelial cells within cell 
clusters 85.7% (6/7) N/A Purkait et al. (18) 
Endothelial wrapping 20% (8/40) 0.0053 Bongiovanni et al. (15) 
 71.4% (5/7) N/A Purkait et al. (18) 
Peripheral orientation of nuclei in cell 
clusters 71.4% (5/7) N/A Purkait et al. (18) 
Cellular features    
High N/C ratio 67.5% (27/40) <0.0001 Bongiovanni et al. (15) 
 100% (10/10) N/A Barwad et al. (16) 
 93.2% (41/44) <0.001 Kane et al. (17) 
Small cell size 93.2% (41/44) <0.001 Kane et al. (17) 
Plasmacytoid appearance 25% (10/40) 0.0007 Bongiovanni et al. (15) 
Cytoplasm    
Scant  87.5% (35/40) 0.03 Bongiovanni et al. (15) 
 30% (3/10) N/A Barwad et al. (16) 
Moderate 60% (6/10) N/A Barwad et al. (16) 
Nuclear features    
Atypia 55% (22/40) <0.0001 Bongiovanni et al. (15) 
Pleomorphism 40% (16/40) 0.0052 Bongiovanni et al. (15) 
 86.4 (38/44) <0.0001 Kane et al. (17) 
Anisokaryosis 50% (20/40) <0.0001 Bongiovanni et al. (15) 
Crowding/nuclear overlapping 85.7% (6/7) N/A Purkait et al. (18) 
 70% (28/40) <0.0001 Bongiovanni et al. (15) 
 88.6% (39/44) <0.001 Kane et al. (17) 
Granular/coarse chromatin 40% (16/40) 0.026 Bongiovanni et al. (15) 
 80% (8/10) N/A Barwad et al. (16) 
 95.5% (42/44) <0.001 Kane et al. (17) 
Naked nuclei 77.5% (31/40) 0.01 Bongiovanni et al. (15) 
Mitotic activity 42.5% (17/40) 0.0001 Bongiovanni et al. (15) 
 9/10 (90%) N/A Barwad et al. (16) 
 25% (11/44) <0.001 Kane et al. (17) 
Apoptosis 45% (18/40) <0.0001 Bongiovanni et al. (15) 
 45% (20/44) <0.001 Kane et al. (17) 
N/C, Nuclear/cytoplasmic; N/A, Not available 
 





